Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Devices support Johnson & Johnson quarter 1 growth while observers mull acquisitions

This article was originally published in Clinica

Executive Summary

While Johnson & Johnson may have lost out to Boston in its bid to acquire Guidant, the diversified healthcare company could at least console itself with having gained $368m as compensation from Guidant for terminating their previous merger agreement. The one-off gain boosted J&J's first-quarter net earnings to $3.3bn - up 16.4% from the previous year - and more than offset $29m in acquisition charges incurred during that period.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT051487

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel